Found 122 articles
Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023
Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy 26th Annual Meeting in Los Angeles.
Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting
Chroma Medicine, Inc. announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform.
Chroma Medicine to Present First Data Demonstrating Promise of Its Epigenetic Editing Platform at 26th ASGCT Annual Meeting
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced two oral data presentations that showcase the potential of its epigenetic editing platform at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
Apollomics Inc. announced that the company’s Co-Founder and President, Sanjeev Redkar, MBA, Ph.D., will speak at the 23rd Annual R. Bryan Miller Symposium, an event exploring the interface of chemical biology and organic chemistry in honor of Professor R. Bryan Miller, at the University of California, Davis on April 14, 2023.
Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.
Backed by Google Ventures, ARCH Venture Partners and more, Chroma Medicine announced the closing of a $135 million Series B financing Wednesday.
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
Chroma Medicine, Inc. announced the completion of a $135 million Series B financing led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management.
Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts
Alterome Therapeutics, Inc. today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
Generate Biomedicines Uses AI to Create Proteins That Have Never Existed
Generate Biomedicines today published a preprint describing a breakthrough in protein science that unlocks the ability to generate novel proteins.
SeQure Dx Emerges From Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies for Biopharma Partners, Physicians, and Patients
SeQure Dx has announced its emergence from stealth mode with an aim to partner with biopharma companies developing gene editing therapeutics.
Bridgewest Group inks deal with Pfizer to acquire injectable manufacturing plant in Western Australia
Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, is expanding its portfolio.
Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors
Expansion Therapeutics, Inc. today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management.
Chroma Medicine Welcomes Spark Therapeutics Co-Founder and Former Founding CEO Jeff Marrazzo to Board of Directors
Chroma Medicine , Inc. today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors.
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB).
Myeloid Therapeutics Strengthens its Board of Directors with Appointments of Stanley Frankel, M.D., FACP and Brett Kaplan, M.D.
Myeloid Therapeutics, Inc. today announced that it has expanded its Board of Directors with the appointments of industry leaders Stanley Frankel, M.D., FACP and Brett Kaplan, M.D.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Chroma Medicine Strengthens Leadership with Addition of George Golumbeski to Board of Directors and John Maraganore as Strategic Advisor
Chroma Medicine Strengthens Leadership with Addition of George Golumbeski to Board of Directors and John Maraganore as Strategic Advisor.
Etcembly Appoints Scott Cuthill as Chief Business Officer
Etcembly today announced the appointment of Scott Cuthill PhD, as Chief Business Officer (CBO). The Oxford based company is harnessing the power of the adaptive immune system to transform the precision, scale and speed of development of TCR immunotherapies.
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.